{
  "ticker": "AARD",
  "company_name": "Aardvark Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05153434",
      "title": "A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Prader-Willi Syndrome",
      "start_date": "2022-05-27",
      "completion_date": "2024-09-24",
      "enrollment": 0,
      "sponsor": "Aardvark Therapeutics, Inc."
    },
    {
      "nct_id": "NCT06126653",
      "title": "A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Autism Spectrum Disorder",
      "start_date": "2024-08-01",
      "completion_date": "2025-01-13",
      "enrollment": 0,
      "sponsor": "Aardvark Therapeutics, Inc."
    },
    {
      "nct_id": "NCT07197034",
      "title": "The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Hyperphagia, Prader-Willi Syndrome, Hyperphagia in Prader-Willi Syndrome",
      "start_date": "2024-07-23",
      "completion_date": "2027-04",
      "enrollment": 0,
      "sponsor": "Aardvark Therapeutics, Inc."
    },
    {
      "nct_id": "NCT06828861",
      "title": "ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Hyperphagia, Prader-Willi Syndrome",
      "start_date": "2024-12-20",
      "completion_date": "2026-04",
      "enrollment": 0,
      "sponsor": "Aardvark Therapeutics, Inc."
    },
    {
      "nct_id": "NCT05215847",
      "title": "Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Bariatric Surgery, Obesity, Weight Gain",
      "start_date": "2022-03-01",
      "completion_date": "2023-02-03",
      "enrollment": 0,
      "sponsor": "Aardvark Therapeutics, Inc."
    },
    {
      "nct_id": "NCT05121441",
      "title": "Study to Evaluate ARD-101 in Adults With Obesity",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Obesity",
      "start_date": "2021-11-15",
      "completion_date": "2022-11-09",
      "enrollment": 0,
      "sponsor": "Aardvark Therapeutics, Inc."
    }
  ],
  "summary": {
    "total_trials": 6,
    "by_phase": {
      "PHASE2": 4,
      "PHASE3": 2
    },
    "by_status": {
      "COMPLETED": 4,
      "RECRUITING": 2
    },
    "active_trials": 2,
    "completed_trials": 4,
    "conditions": [
      "Autism Spectrum Disorder",
      "Bariatric Surgery, Obesity, Weight Gain",
      "Hyperphagia, Prader-Willi Syndrome",
      "Hyperphagia, Prader-Willi Syndrome, Hyperphagia in Prader-Willi Syndrome",
      "Obesity",
      "Prader-Willi Syndrome"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:15:47.558974",
    "search_query": "Aardvark Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Aardvark+Therapeutics,+Inc."
  }
}